Premium
Degradation of radiolabelled arginine vasopressin ( 125 I‐AVP) by the human placenta perfused in vitro
Author(s) -
LANDON M. J.,
COPAS DEBBIE K.,
SHIELLS ELIZABETH A.,
DAVISON J. M.
Publication year - 1988
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1988.tb12802.x
Subject(s) - vasopressin , arginine , oxytocin , placenta , endocrinology , human placenta , medicine , fetal circulation , in vitro , fetus , neuropeptide , biology , chemistry , pregnancy , biochemistry , amino acid , receptor , genetics
Summary. The capacity of the human placenta to degrade 125 I‐labelled arginine vasopressin ( 125 I‐AVP) was studied in vitro using a dual circuit perfused lobule preparation. Seven placentas were perfused with the perfusate on the maternal side of the lobule containing 125 I‐AVP at the upper limit of the physiological range. On average, over a 30‐min period, 48% of the 125 I‐AVP appeared to have been metabolized. With one exception, a patient whose labour was augmented with intravenous oxytocin, no 125 T‐AVP apparently crossed the placental lobule to the fetal circulation. These data indicate that the human placenta has a considerable capacity to degrade AVP.